SynBiotic SE (DUSE:SBX)
Germany · Delayed Price · Currency is EUR 0.1522
-0.7278 (-82.70%)
At close: Oct 20, 2026
SynBiotic SE Revenue
SynBiotic SE had revenue of 36.61K EUR in the quarter ending June 30, 2025, a decrease of -6.16%. In the year 2024, SynBiotic SE had annual revenue of 14.89M with 265.26% growth.
Revenue
14.89M
Revenue Growth
+265.26%
P/S Ratio
0.08
Revenue / Employee
188.08K
Employees
79
Market Cap
1.13M
Revenue by Geography
- Germany 10.01M 70.0%
- European Countries 4.29M 30.0%
Fiscal year ended Dec 31, 2024 See the full SynBiotic SE breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.89M | 10.81M | 265.26% |
| Dec 31, 2023 | 4.08M | -4.60M | -53.03% |
| Dec 31, 2022 | 8.68M | -387.29K | -4.27% |
| Dec 31, 2021 | 9.06M | 3.59M | 65.63% |
| Dec 31, 2020 | 5.47M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.38B |
| Fresenius SE & Co. KGaA | 23.28B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| Maternus-Kliniken Aktiengesellschaft | 119.35M |
| Biofrontera AG | 15.97M |
| SynBiotic SE | 14.86M |
| Geratherm Medical AG | 13.97M |
SynBiotic SE News
- 2 months ago - Portfolio unwound; rating placed Under Review: Wave of portfolio insolvencies narrows SYNBIOTIC to WEECO ... - Finanz Nachrichten
- 2 months ago - Portfolio unwound; rating placed Under Review - Wallstreet:Online